{"id":"continuation-phase-fluoxetine","safety":{"commonSideEffects":[{"rate":"20-25","effect":"Nausea"},{"rate":"15-20","effect":"Headache"},{"rate":"10-15","effect":"Insomnia"},{"rate":"10-15","effect":"Sexual dysfunction"},{"rate":"10-12","effect":"Diarrhea"},{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Somnolence"}]},"_chembl":{"chemblId":"CHEMBL1201082","moleculeType":"Small molecule","molecularWeight":"345.79"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluoxetine selectively inhibits the reuptake of serotonin at the synaptic cleft, leading to increased serotonin concentration and enhanced neurotransmission. This mechanism is thought to improve mood and reduce symptoms of depression and anxiety disorders. The continuation phase refers to maintenance therapy following an acute treatment phase to prevent relapse.","oneSentence":"Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the presynaptic neuron.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:28.629Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder (continuation/maintenance phase)"},{"name":"Obsessive-compulsive disorder"},{"name":"Panic disorder"},{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT02977299","phase":"PHASE4","title":"Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-05-01","conditions":"Treatment Resistant Major Depressive Disorder","enrollment":278},{"nctId":"NCT02017535","phase":"PHASE1, PHASE2","title":"An Adaptive Treatment Strategy for Adolescent Depression-Continuation","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2012-06","conditions":"Adolescent Depression","enrollment":15},{"nctId":"NCT00118430","phase":"PHASE4","title":"Stepped Care for Depression and Musculoskeletal Pain","status":"COMPLETED","sponsor":"Indiana University","startDate":"2004-09","conditions":"Pain, Depression","enrollment":500},{"nctId":"NCT01305707","phase":"PHASE4","title":"Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2009-07","conditions":"Depression","enrollment":104},{"nctId":"NCT00118404","phase":"PHASE3","title":"Cognitive Therapy for Recurrent Depression","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2000-03","conditions":"Depression","enrollment":523},{"nctId":"NCT00332787","phase":"NA","title":"Determining Optimal Continuation Treatment Duration for Depressed Children and Adolescents","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2000-06","conditions":"Depression","enrollment":200},{"nctId":"NCT00158301","phase":"NA","title":"Cognitive Behavioral Therapy for Depression Relapse Prevention in Children and Adolescents","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2004-09","conditions":"Depression","enrollment":72},{"nctId":"NCT00427128","phase":"PHASE4","title":"Prozac Treatment of Major Depression: Discontinuation Study","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"1995-11","conditions":"Major Depression","enrollment":627},{"nctId":"NCT00046020","phase":"PHASE4","title":"Study Evaluating Venlafaxine ER in Recurrent Depression","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2000-08","conditions":"Depressive Disorder, Major, Recurrence","enrollment":1096}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":146,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prozac"],"phase":"phase_3","status":"active","brandName":"Continuation phase fluoxetine","genericName":"Continuation phase fluoxetine","companyName":"University of Texas Southwestern Medical Center","companyId":"university-of-texas-southwestern-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the presynaptic neuron. Used for Major depressive disorder (continuation/maintenance phase), Obsessive-compulsive disorder, Panic disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}